The genomes of cancers deficient in mismatch repair contain exceptionally high numbers of
somatic mutations. In a proof-of-concept study, we previously showed that colorectal …

Background Antibodies that block programmed death 1 (PD-1) protein improve survival in
patients with advanced non–small-cell lung cancer (NSCLC) but have not been tested in …

Immune checkpoint inhibitors have shown significant therapeutic responses against tumors
containing increased mutation-associated neoantigen load. We have examined the evolving …

PD-1 blockade unleashes CD8 T cells 1 , including those specific for mutation-associated
neoantigens (MANA), but factors in the tumour microenvironment can inhibit these T cell …

Tumor mutation burden is an imperfect proxy of tumor foreignness and has therefore failed
to consistently demonstrate clinical utility in predicting responses in the context of …

The molecular diversity of rumen methanogens in sheep in Australia was investigated by
using individual 16S rRNA gene libraries prepared from the rumen contents obtained from six …

… Kellie N. Smith … Marrone, IKA Sivakumar, DC Bruhm, KN Smith, TR Cottrell, CL Hann, B.
Levy, J. Feliciano, P. …

Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …

Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent approval
of combination immune checkpoint blockade. Here we report the results of the phase 2 …

Background We conducted the first trial of neoadjuvant PD-1 blockade in resectable non-small
cell lung cancer (NSCLC), finding nivolumab monotherapy to be safe and feasible with …